Personal information

Activities

Employment (2)

Université de Lorraine: VANDOEUVRE LES NANCY, FR

2005-02 to present | Enseignant Chercheur (IUT Nancy Brabois, Génie Biologique Santé)
Employment
Source: Self-asserted source
Sandrine GULBERTI

UMR 73 65 Université de Lorraine CNRS, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA): Vandœuvre-lès-Nancy, FR

2005-02 to present | Enseignant Chercheur (Equipe MolCelTEG (Molecular and Cellular Therapeutic Engineering and Glycosyltransferases))
Employment
Source: Self-asserted source
Sandrine GULBERTI

Education and qualifications (4)

Diplôme Universitaire (DU) d’expérimentation animale de niveau I (concepteur): Nancy, FR

2005 to present | DU (Faculté de Pharmacie)
Education
Source: Self-asserted source
Sandrine GULBERTI

Pharmacologie, Métabolisme et Mécanisme d’Action des Médicaments-Pharmacologie clinique: Nancy, FR

2003 to present | Doctorat (Faculté de Pharmacie)
Qualification
Source: Self-asserted source
Sandrine GULBERTI

Pharmacologie, Métabolisme et Mécanisme d’Action des Médicaments-Pharmacologie clinique: Nancy, FR

1999 to present | DEA (Master2) (Faculté de Pharmacie)
Qualification
Source: Self-asserted source
Sandrine GULBERTI

Biochimie: Vandœuvre-lès-Nancy, FR

1998 to present | Maitrise (Master1) (Faculté des Sciences)
Qualification
Source: Self-asserted source
Sandrine GULBERTI

Professional activities (4)

GDR GAGosciences: Grenoble, FR

2016 to present | CNRS
Membership
Source: Self-asserted source
Sandrine GULBERTI

Expert IRTF (Ingénieurs et personnels Techniques de Recherche et de Formation): Nancy, FR

2013 to present | Expert (B.A.P. A : Sciences du vivant, de la terre et de l'environnement)
Service
Source: Self-asserted source
Sandrine GULBERTI

Société Française de Biochimie et Biologie Moléculaire (SFBBM): Paris, FR

2010 to present
Membership
Source: Self-asserted source
Sandrine GULBERTI

Groupe Français de Glycosciences (GFG): Paris, FR

2010 to present
Membership
Source: Self-asserted source
Sandrine GULBERTI

Funding (1)

Development of a specific inhibitor of the glycosyltransferase β4GalT7 for substrate reduction therapy in mucopolysaccharidoses: towards the hit to lead stage

2021-04 to 2022-10 | Grant
Fondation Maladies Rares (Paris, FR)
Source: Self-asserted source
Sandrine GULBERTI